Bernard De Bruyne.

Pim A.L tadalafiloverthecounter.com . Tonino, M.D., Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Uwe Siebert, M.D., M.P.H., Sc.D., Fumiaki Ikeno, M.D., Marcel van `t Veer, M.Sc., Volker Klauss, M.D., Ph.D., Ganesh Manoharan, M.D.D., Ph.D., Keith G. Oldroyd, M.D., Peter N. Ver Lee, M.D., Philip A. MacCarthy, M.D., Ph.D., and William F. Fearon, M.D. For the FAME Research Investigators: Fractional Movement Reserve versus Angiography for Guiding Percutaneous Coronary Intervention The current presence of myocardial ischemia can be an important risk factor for a detrimental clinical outcome.1-3 Revascularization of stenotic coronary lesions that induce ischemia can improve a patient’s practical status and outcome.3-5 For stenotic lesions that do not induce ischemia, however, the advantage of revascularization is less clear, and medical therapy alone is likely to be effective equally.6,7 With the introduction of drug-eluting stents, the %age of patients with multivessel coronary artery disease in whom percutaneous coronary intervention is conducted has increased.8,9 Because drug-eluting stents are costly and are associated with potential late complications, their appropriate use is critical.10,11 However, in individuals with multivessel coronary artery disease, determining which lesions trigger ischemia and warrant stenting can be difficult.

Remon Medical has finished the enrollment for its clinical trial of the Remon ImpressureTM, a device that offers on-demand, noninvasive methods to monitor intra-aneurysm pressures pursuing endo-vascular graft procedures. The device was implanted and being used successfully in 20 individuals in the Mount Sinai Hospital . Remon Medical also evolves the Remon HeartLookTM, a device for measurement of pulmonary artery pressure – the most crucial hemodynamic indicator in heart failure.. $16 million investment in minute wireless implant technology Remon Medical Technologies a held medical device company privately, today announced that it has raised $16 million in the initial close of a string C funding.